Drug profile · INN
eculizumab-aagh
EPYSQLI
eculizumab-aagh (EPYSQLI) is a complement c5 inhibitor. Route of administration: solution. Current US regulatory status: approved.
Drug details — eculizumab-aagh
- US status
- approved
- Class
- —
- Route
- SOLUTION
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
eculizumab-aagh (EPYSQLI) is a complement c5 inhibitor. Route of administration: solution. Current US regulatory status: approved.
Key facts
Mechanism of action
Complement C5 inhibitor
Primary target: Complement C5
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is eculizumab-aagh?
eculizumab-aagh (EPYSQLI) is a complement c5 inhibitor. Route of administration: solution. Current US regulatory status: approved.
What is the brand name for eculizumab-aagh?
EPYSQLI is a marketed brand name for eculizumab-aagh. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of eculizumab-aagh?
eculizumab-aagh has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.